TORONTO, Oct. 28, 2015 /CNW/ -- Bionik Laboratories Corp. (OTCQX: BNKL), a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders ("Bionik" or the "Company"), today announced the Company met with His Royal Highness Prince Edward, Earl of Wessex during his visit to the DMZ at Ryerson University on Tuesday, October 27, 2015.
Bionik Laboratories management was one of three innovative tech companies to meet with His Royal Highness Prince Edward, Earl of Wessex on Tuesday, October 27 at 11 a.m. at the DMZ at Ryerson University. The Honourable Elizabeth Dowdeswell, Lieutenant Governor of Ontario, accompanied the Earl to hear from the young entrepreneurs. Included in the meeting was a demonstration of Bionik's proprietary lead program, ARKE™, the Company's lower-body exoskeleton robotic device which could allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion.
"We were honored to have met with Prince Edward, Earl of Wessex and to take part in building into the legacy of innovative tech founders at the DMZ at Ryerson University," stated Mr. Prywata, the Company's Chief Operating Officer. "We believe our patented ARKE exoskeleton has the potential to transform the future for mobility impaired patients. We continue to work in earnest to develop the technology, manageability and structural strength to create a more effective rehabilitation product."
Following the presentation, a roundtable discussion with the focus of fostering a culture of innovation took place with the Bionik management team and other young entrepreneurs attending the meeting.
About The DMZ at Ryerson University
Founded in 2010, the DMZ (formerly the Digital Media Zone) at Ryerson University is one of Canada's largest business incubators for emerging tech startups. The DMZ is the top-ranked university incubator in Canada and fifth in the world, offering space and community that supports and fosters new technologies that transform lives and businesses. Five years after launching, more than 180 startups have incubated at the DMZ. They've raised over $70 million in seed funding and have fostered the creation of more than 1,500 jobs. They've acquired customers, won awards, grown their teams, and developed products and solutions that are positively changing lives and businesses in Canada and abroad.
About Bionik Laboratories
Bionik Laboratories (OTCQX: BNKL) is a pioneering medical device and robotics company with a focus in developing technologies and solutions for individuals with neurological disorders. The Bionik team has researched, developed and tested its primary product, The ARKE™, a robotic lower-body exoskeleton device that allows paraplegics as well as other wheelchair users the ability to rehabilitate through walking and other motion. Bionik recently successfully raised approximately US$13.1 million which enables the company to rapidly advance its development and growth strategy. For more information, please visit www.bioniklabs.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including, the Company's current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.
SOURCE Bionik Laboratories Corp.
For further information: Bionik Laboratories, Inc. Contact: Jenene Thomas, Jenene Thomas Communications, LLC, (908) 938-1475, [email protected], http://www.bioniklabs.com